Characterisation of People With COPD (CoCO)

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
National Services for Health Improvement Ltd
ClinicalTrials.gov Identifier:
NCT01263340
First received: December 16, 2010
Last updated: December 4, 2013
Last verified: December 2013
  Purpose

The investigators will describe the characteristics, prevalence, incidence, severity co-morbidity and management of patients with chronic obstructive pulmonary disease (COPD) in the UK. 100 practices will be sampled amounting to a total study population of about 10 000 patients. Information will be collected electronically and, where necessary, by a hand search of patient records.


Condition
Chronic Obstructive Pulmonary Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Observational, Multi-centre, Retrospective Cohort Study to Evaluate Prevalence, Incidence, Severity, Co-morbidities and Burden of Disease in Patients With a Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) by Close Scrutiny of the Patient Journey

Resource links provided by NLM:


Further study details as provided by National Services for Health Improvement Ltd:

Primary Outcome Measures:
  • Prevalence and characterisation of people with COPD [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 10000
Study Start Date: December 2010
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
People with COPD

  Show Detailed Description

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

People with a Read code diagnosis of COPD

Criteria

Inclusion Criteria:

  • people with a read code diagnosis of COPD

Exclusion Criteria:

  • none
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01263340

Locations
United Kingdom
NHS primary care centres
Nationwide, United Kingdom
Sponsors and Collaborators
National Services for Health Improvement Ltd
GlaxoSmithKline
Investigators
Principal Investigator: John Haughney, FRCPE FRCGP NSHI Ltd
  More Information

No publications provided by National Services for Health Improvement Ltd

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: National Services for Health Improvement Ltd
ClinicalTrials.gov Identifier: NCT01263340     History of Changes
Other Study ID Numbers: SCO115217
Study First Received: December 16, 2010
Last Updated: December 4, 2013
Health Authority: United Kingdom: Research Ethics Committee

Keywords provided by National Services for Health Improvement Ltd:
COPD
observational study
prevalence
characterisation

Additional relevant MeSH terms:
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on July 23, 2014